ATNM: Potential turning point ahead of Phase 2 results
Immuno-oncology stock that has recently completed an offering of common stock @ $0.75 per share. Stock looks to have bottomed out. Buy a for a potential 10-20% bounce.
Exención de responsabilidad
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Exención de responsabilidad
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.